Credit Suisse ups C4 Therapeutics to Neutral on ‘dramatically’ improved outlook

As previously reported, Credit Suisse analyst Richard Law upgraded C4 Therapeutics to Neutral from Underperform with a price target of $10, down from $12, after the company reported Q4 financial results. With four assets in clinical development, the firm believes the company’s outlook has "improved dramatically," but despite its optimism about an improved outlook, Credit Suisse continues to see high barriers in intensely competitive markets for the four assets to succeed individually, keeping it from upgrading the stock to an Outperform rating.